California Healthline senior correspondent Angela Hart appeared on KCRW’s “Press Play With Madeleine Model” and KJZZ, a public radio station in Phoenix, this month to debate California’s plan to cut back the price of some prescription medicines — beginning with insulin — by diving into the generic drug market.
California lawmakers put aside $100 million within the not too long ago adopted 2022-23 state funds to assist launch the CalRx drug label, and the state may begin producing generic insulin throughout the subsequent few years, in accordance with Gov. Gavin Newsom’s administration. The objective is to make the drug out there to thousands and thousands of Californians by way of pharmacies, retail shops, and mail order, administration officers say.
Initially, the state would contract with a drug producer to make and distribute the drug, which at present prices about $300 to $400 per vial with out insurance coverage. Many questions stay unanswered, similar to how cheaply insulin may very well be produced and what sufferers would pay.
“By way of the fee, there are some firms which might be speaking about producing this for about … $30 a vial,” Hart advised KCRW.
|
This text was reprinted from khn.org with permission from the Henry J. Kaiser Household Basis. Kaiser Well being Information, an editorially impartial information service, is a program of the Kaiser Household Basis, a nonpartisan well being care coverage analysis group unaffiliated with Kaiser Permanente. |